Citadel Advisors
INMB icon

Citadel Advisors’s INmune Bio INMB Stock Holding History

Citadel Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Buy
16,800
+4,300
+34% +$5.95K ﹤0.01% 13325
2026
Q1 		$14.1K Sell
12,500
-33,200
-73% -$47.3K ﹤0.01% 12719
2025
Q4 		$71.3K Sell
45,700
-154,900
-77% -$276K ﹤0.01% 11860
2025
Q3 		$415K Sell
200,600
-247,200
-55% -$566K ﹤0.01% 9572
2025
Q2 		$1.03M Buy
447,800
+433,000
+2,926% +$3.18M ﹤0.01% 7011
2025
Q1 		$116K Sell
14,800
-47,700
-76% -$379K ﹤0.01% 11257
2024
Q4 		$292K Buy
62,500
+33,200
+113% +$173K ﹤0.01% 9711
2024
Q3 		$158K Buy
29,300
+16,900
+136% +$120K ﹤0.01% 10500
2024
Q2 		$109K Sell
12,400
-9,000
-42% -$88.7K ﹤0.01% 10794
2024
Q1 		$251K Buy
21,400
+12,600
+143% +$152K ﹤0.01% 9852
2023
Q4 		$99.1K Sell
8,800
-1,300
-13% -$10.9K ﹤0.01% 10948
2023
Q3 		$69.1K Sell
10,100
-2,700
-21% -$22.4K ﹤0.01% 11337
2023
Q2 		$116K Sell
12,800
-3,200
-20% -$25.7K ﹤0.01% 10710
2023
Q1 		$103K Sell
16,000
-12,400
-44% -$99.9K ﹤0.01% 11215
2022
Q4 		$180K Sell
28,400
-500
-2% -$3.55K ﹤0.01% 10318
2022
Q3 		$179K Buy
28,900
+6,400
+28% +$56.2K ﹤0.01% 10514
2022
Q2 		$199K Sell
22,500
-6,400
-22% -$47.6K ﹤0.01% 10694
2022
Q1 		$243K Sell
28,900
-16,300
-36% -$146K ﹤0.01% 11071
2021
Q4 		$461K Buy
45,200
+7,200
+19% +$107K ﹤0.01% 9897
2021
Q3 		$738K Sell
38,000
-17,400
-31% -$336K ﹤0.01% 8921
2021
Q2 		$973K Buy
+55,400
New +$747K ﹤0.01% 8436

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's INMB Position: Q2 2026 in Review

Citadel Advisors opened a new position in INmune Bio (INMB) in Q2 2026: 106,231 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #12221 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INMB as recently as Q1 2025.

Citadel Advisors first reported a position in INMB in Q1 2019 and has held it in 18 quarters since. The position peaked at $1.02M in Q3 2021. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Citadel Advisors held 106,231 shares of INmune Bio worth $173K as of Q2 2026.
  • INmune Bio was a new Citadel Advisors position in Q2 2026.
  • INmune Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12221 holding.
  • Citadel Advisors first reported a position in INmune Bio in Q1 2019 and has held it in 18 quarters since.
  • Citadel Advisors's INmune Bio position peaked at $1.02M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.